Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All drugs

Cetilistat

Stage Phase 1Stale

Sponsor Alizyme

Sources

registry, as of 2007-04-11Stale

https://clinicaltrials.gov/study/NCT00148382

Study of the Blood Levels and Effects of ATL-962 on Fat Excretion in Obese Subjects. Overall status COMPLETED. Phases PHASE1. Lead sponsor Alizyme. Enrollment 80. Conditions Obesity. The purpose of this study is to investigate the amount of metabolites of ATL-962 in the blood and to investigate the effect of ATL-962 on the amount of fat that is excreted in the faeces in subjects who are obese

ClinicalTrials.gov NCT00148382 protocol and results modules

Studies

Study of the Blood Levels and Effects of ATL-962 on Fat Excretion in Obese Subjects

Registry NCT00148382

Phase Phase 1

Status Completed

Enrollment 80

Registry arm not named

Population Obesity